首页 /药靶模型 /药靶细胞 /免疫治疗 /HHLA2(B7H7) aAPC Cell

HHLA2(B7H7) aAPC Cell

CBP74194

询 价
索取Protocol
产品描述
产品数据库
I. Background
HHLA2 (a B7 family member) has both immune inhibitory and activating abilities and is expressed in many human cancers. These differing functions rely on the receptor to which it binds, yet many of these receptors are uncharacterized. Here, Wei et al. found that KIR3DL3 bound to HHLA2 and was expressed on effector memory CD8+ T cells and CD56dim NK cells. Interactions of KIR3DL3 with tumoral HHLA2 inhibited the function and killing capacity of both CD8+ T cells and NK cells. KIR3DL3+ immune cells infiltrated various types of HHLA2+ tumors from patients with cancer, and blockade of KIR3DL3 inhibited the growth of tumors in various mouse models. Thus, KIR3DL3-HHLA2 inhibits immune-mediated clearance of tumor cells and presents a possible immunotherapeutic target for cancer.
 
II. Introduction
Expressed gene: HHLA2(B7H7)
Stability: 32 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.)
Freeze Medium: 90% FBS+10% DMSO
Culture Medium: F12K+10%FBS+2ug/ml puromycin+500ug/ml hygromycin
Mycoplasma Testing: Negative
Storage: Liquid nitrogen
Application(s): Functional(Report Gene) Assay
 
III. Representative Data

Figure 1.Recombinant HHLA2(B7H7) aAPC Cell stably expressing HHLA2(B7H7).

Figure 2. Dose Response of HHLA2 Blocking Abs in KIR3DL3 Effector Reporter Cells (C1)With HHLA2(B7H7) aAPC Cells.

Figure 3. Dose Response of HHLA2 Blocking Abs in TMIGD2 Effector Reporter Cells (C1) With HHLA2(B7H7) aAPC Cells.

 

药靶模型联系方式: 华东销售经理:18240630236 全国销售经理:18066071954
诊断标准品联系方式: 华东销售经理:15000320447 华北销售经理:18131625521 华南销售经理:13484295986 华中&西南销售经理:13871580511 全国销售经理:13484295986

扫二维码

立即提交